TOP > 外国特許検索 > VACCINE AGAINST PATHOGENIC GRAM-NEGATIVE BACTERIA

VACCINE AGAINST PATHOGENIC GRAM-NEGATIVE BACTERIA NEW

外国特許コード F190009792
整理番号 S2017-0291-C0
掲載日 2019年5月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP003991
国際公開番号 WO 2018147265
国際出願日 平成30年2月6日(2018.2.6)
国際公開日 平成30年8月16日(2018.8.16)
優先権データ
  • 特願2017-020501 (2017.2.7) JP
発明の名称 (英語) VACCINE AGAINST PATHOGENIC GRAM-NEGATIVE BACTERIA NEW
発明の概要(英語) The present invention provides a vaccine against pathogenic gram-negative bacteria, the vaccine comprising a V antigen of a type III secretion system, a homolog protein thereof, a part thereof, or a gene encoding the V antigen, and a CpG oligodeoxynucleotide (CpG ODN) adjuvant.
従来技術、競合技術の概要(英語) BACKGROUND ART
In accordance with the aging and highly advanced medical, multi-drug resistant bacteria by many lethal infection has been reported. In particular, opportunistic infections and ventilator-associated pneumonia intensive target high frequency of disease-bacteria-resistant Pseudomonas aeruginosa highly rapidly advanced and multi-agent, an antimicrobial agent that does not rely on, to enhance the immunity to the vaccine development is in strong demand.
Pseudomonas aeruginosa many pathogenic gram negative bacteria, eukaryotic cells and in direct contact with the target, type III secretion system (TTSS) special used, directly, in the cytoplasm of the target protein toxin is transferred to (Fig. 1). Is against the pathogenic, not antibody to a toxin, toxin secretion inhibition or, the enzymatic action of toxin or transition needs to be suppressed. Pseudomonas aeruginosa is one toxin 4 through the TTSS (ExoS, T, U, Y) is injected into the target cell results in the inhibition or cell death to phagocytize the toxicological agents (Fig. 2) (Non-Patent Document 1). Toxin is injected into the target cell of the quality, type III secretion system structure of the tip of the target cell is formed on the pores is required, these are one of the 3 protein (PcrV, PopB, PopD) (Fig. 3) is configured. Particularly PcrV the protein, and antigen homolog of Yersinia pestis LcrV and V, the present inventor et al. has the effect of vaccines against Pseudomonas aeruginosa infection was found (Non-Patent Document 2). After, the secretion of the type III secretion system PcrV of the pentamer cap portion at a leading end of the protrusion (Fig. 3) constituting the structure, specific antibodies PcrV toxin (Non-Patent Document 3-5) of the pores have been found to inhibit the passage. The present inventors have found this to result in an animal model antibody therapy, bacteriological human, on the basis of epidemiologic such as serum, human vaccines for Pseudomonas aeruginosa is applicable to clinical development has been performed (non-patent document 6-7).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
  • National Institutes of Biomedical Innovation, Health and Nutrition
  • 発明者(英語)
  • SAWA, Teiji
  • ISHII, Ken
  • HAMAOKA, Saeko
  • NAITO, Yoshifumi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close